Dr. Robert Winn, an expert on
cancer mutations, explains the importance of combination therapies for BRAF mutations in non-small-cell lung cancer.
BRAF mutations are targeted with combination, or two-drug, therapy. He explains how using more than one drug can be more effective at treating
non-small-cell lung cancer and how this approach applies to other mutations as well.
-
Share with family and friends:
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.